Kenai Therapeutics
PrivateLast Round
Grant
Jan 5, 2026
Total Funding Raised
$97M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kenai Therapeutics is a biotechnology company that develops off-the-shelf neuron replacement therapies for neurological disorders such as Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kenai Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Kenai Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 5, 2026 | ||||
| Series A | Feb 29, 2024 | ||||
| Grant | Feb 14, 2023 | ||||
| Seed | Jul 19, 2022 |
Key People
Founding team and executive leadership
Kenai Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series A |
| Saisei Ventures | Series A, Seed |
| The Chernin Group | Series A |
| California Institute for Regenerative Medicine | Grant |
| Cure Ventures | Series A |
| Euclidean Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 12, 2026
Allen Waldrop appointed to the Board of Directors.
- Feb 24, 2026
Blake Arnold appointed as new Chief Business Officer.
Kenai Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Kenai Therapeutics's valuation, stock price, and market status.